Hemab Therapeutics’ (COAG) Buy Rating Reaffirmed at HC Wainwright

Hemab Therapeutics (NASDAQ:COAG)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $40.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 27.31% from the stock’s current price.

A number of other brokerages also recently issued reports on COAG. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. The Goldman Sachs Group started coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target on the stock. Wedbush began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $42.00 price target for the company. Finally, Evercore started coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $41.40.

Hemab Therapeutics Stock Up 13.3%

NASDAQ:COAG traded up $3.70 during trading hours on Friday, reaching $31.42. The company had a trading volume of 96,027 shares, compared to its average volume of 254,728. Hemab Therapeutics has a 52 week low of $23.00 and a 52 week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last released its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity at Hemab Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 2,675,000 shares of the stock in a transaction dated Monday, May 4th. The stock was bought at an average cost of $18.00 per share, with a total value of $48,150,000.00. Following the purchase, the director directly owned 6,149,096 shares of the company’s stock, valued at approximately $110,683,728. This represents a 77.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have bought 2,970,541 shares of company stock worth $55,459,603.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.